ROS-Responsive Nanosystem Targeted Co-Delivery YC-1 and Regorafenib to Alleviate Hypoxia Enhancing Hepatocellular Carcinoma Therapy
International Journal of Nanomedicine · 2025-07 · Volume 20 · 8481-8496
DOI: 10.2147/ijn.s518120 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2025-07. Verfasst von Liming Song und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People's Republic of Ch…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Pyridines, Indazoles. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
The current treatment of hepatocellular carcinoma (HCC) is confronted with anoxic drug resistance and significant side effects. To address these issues, a Reactive Oxygen Species (ROS)-responsive and targeted nano drug delivery system named REG/YC-1@PTP-RGD NPs (RYP-RGD NPs) was designed for the co-delivery of Regorafenib (REG) and the hypoxia inhibitor 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole (YC-1).
Methods
RYP-RGD NPs were fabricated through the self-assembly method. A series of techniques, such as transmission electron microscopy (TEM), UV-visible spectroscopy, and others, were employed to characterize their properties. In Vitro investigations encompassed drug release assays, cytotoxicity evaluations using Cell Counting Kit-8 (CCK-8) and other methods, cell uptake experiments, and Western blot analysis. In vivo, the biodistribution of RYP-RGD NPs was tracked by IVIS imaging, and their antitumor efficacy and biosafety were assessed in a HepG2 tumor-bearing mouse model with histological staining and biochemical analysis.
Results
RYP-RGD NPs exhibited a spherical morphology with an appropriate size and excellent dispersion. They demonstrated ROS-triggered drug release behavior. In vitro studies revealed good tumor-targeting ability, enhanced cytotoxicity against HCC cells, and the downregulation of hypoxia-inducible factor-1α (HIF-1α) by YC-1. In vivo experiments showed improved tumor targeting, significant inhibition of tumor growth, and lower toxicity compared to single drugs.
Conclusion
The successfully developed RYP-RGD NPs offer a novel strategy for HCC treatment. They enhance drug targeting, synergistically boost the therapeutic effect, and maintain biosafety, showing great potential for clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People's Republic of China.
- Institute of Hepatobiliary and Pancreatic Diseases, Zhengzhou University, Zhengzhou, 450052, People's Republic of China.
- Zhengzhou Basic and Clinical Key Laboratory of Hepatopancreatobiliary Diseases, Zhengzhou, 450052, People's Republic of China.
- Department of Magnetic Resonance Imaging, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People's Republic of China.
- Department of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People's Republic of China.
ORCID-Profile: Yupeng Shi
Zitieren
APA
Song, L., Wu, Y., Zhao, S., Liu, Y., Liu, Z., Zhai, Y., Cao, J., Xia, Y., Liang, R., Wang, W., Zhu, R., Sun, B., Shi, Y., & Sun, Y. (2025). ROS-Responsive Nanosystem Targeted Co-Delivery YC-1 and Regorafenib to Alleviate Hypoxia Enhancing Hepatocellular Carcinoma Therapy. International Journal of Nanomedicine, Volume 20, 8481-8496. https://doi.org/10.2147/ijn.s518120
Vancouver
Song L, Wu Y, Zhao S, Liu Y, Liu Z, Zhai Y, et al. ROS-Responsive Nanosystem Targeted Co-Delivery YC-1 and Regorafenib to Alleviate Hypoxia Enhancing Hepatocellular Carcinoma Therapy. International Journal of Nanomedicine. 2025;Volume 20:8481-8496. doi:10.2147/ijn.s518120
BibTeX
@article{Song2025,
author = {Song, Liming and Wu, Yahui and Zhao, Senfeng and Liu, Yin and Liu, Zhipu and Zhai, Yunpeng and Cao, Jiahui and Xia, Yaning and Liang, Ruopeng and Wang, Weijie and Zhu, Rongtao and Sun, Binghua and Shi, Yupeng and Sun, Yuling},
title = {ROS-Responsive Nanosystem Targeted Co-Delivery YC-1 and Regorafenib to Alleviate Hypoxia Enhancing Hepatocellular Carcinoma Therapy},
journal = {International Journal of Nanomedicine},
year = {2025},
volume = {Volume 20},
pages = {8481--8496},
doi = {10.2147/ijn.s518120}
}
EUVIMED